BioSpace News Archive

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Cowen 40th Annual Healthcare Conference

Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2019, after the market close, and will host a corporate update conference call and webcast on Monday, March 2, 2020, at 4:30 PM Eastern Time.

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Monday, March 2, 2020, to provide a corporate update and discuss details of the Company’s financial results for the quarter and year ended December 31, 2019.

Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that Jeffrey Nau, PhD, MMS, President and CEO, is scheduled to present at the Cowen 40th Annual Healthcare Conference on Monday, March 2, 2020

Feb. 24, 2020 12:58 UTC Shionogi’s FETROJA ® (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the U.S. OSAKA, Japan & FLORHAM PARK, N.J.--( BUSINESS WIRE )-- Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced FETROJA ® (cefiderocol) is now available in the U.S. for patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTIs), includ

Feb. 24, 2020 13:00 UTC -- Twist Comprehensive Exome Offers Maximum Sequence Efficiency with Best Coverage Uniformity to Increase Confidence in Gene Variant Detection -- -- Previews of Twist Targeted Methylation Solution to Investigate Differentially Methylated Regions for Epigenetic and Oncology Research -- -- Speakers from Ancestry, TwinStrand and University of Cambridge to Share Experience with Twist NGS Products -- SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-

IRVINE, Calif. , Feb. 24, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is scheduled to present at the Cowen Healthcare Conference at the Boston Marriott Copley Place on Monday, March 2 , 2020. Scott B. Ull

Randy Cooper, MD presents first four-year data on the vascular access innovation at national nephrology conference

Feb. 24, 2020 13:00 UTC Teva Announces FDA Approval of ArmonAir ® Digihaler™ (fluticasone propionate) Inhalation Powder Teva’s Digital Inhaler Portfolio Now Includes Products from Three of the Most Commonly Prescribed Classes of Asthma Treatments TEL AVIV & PARSIPPANY, N.J.--( BUSINESS WIRE )-- Teva Respiratory, LLC, an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved Arm

Feb. 24, 2020 13:12 UTC MADISON, Wis.--( BUSINESS WIRE )-- Promega Corporation, a global biotechnology manufacturer, today launched its new Wizard® HMW DNA Extraction Kit for researchers working with large fragments of genomic DNA. The kit, as demonstrated in a poster presented at this week’s 2020 Advances in Genome Biology and Technology (AGBT) meeting, enables researchers to obtain DNA that will provide strong performance in long-read sequencing applications in a 90-minute m